Xenon Pharmaceuticals Inc (XENE):企業の財務・戦略的SWOT分析

◆英語タイトル:Xenon Pharmaceuticals Inc (XENE) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH132674FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥87,600見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥131,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that develops medicines to treat neurological disorders. The company is investigating XEN1101, a Kv7 potassium channel modulator against epilepsy; XEN496 for the treatment of seizures associated with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). It is also evaluating XEN007, a CNS-acting calcium channel modulator targeting treatment-resistant childhood absence epilepsy (CAE); and FX-301 to treat post-operative pain. The company partners with Genentech, Flexion Therapeutics Inc and Neurocrine Biosciences Inc to develop and commercialize therapies. Xenon is headquartered in Burnaby, British Columbia, Canada.

Xenon Pharmaceuticals Inc Key Recent Developments

Mar 08,2021: Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)
Feb 23,2021: Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2020 Financial Results
Jan 14,2021: Xenon Pharmaceuticals outlines key milestone opportunities and planned leadership transition in 2021
Nov 05,2020: Xenon Pharmaceuticals reports third quarter 2020 financial results and provides corporate update
Aug 17,2020: Xenon Pharmaceuticals appoints Dr. Chris Von Seggern as chief commercial officer

This comprehensive SWOT profile of Xenon Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Xenon Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Xenon Pharmaceuticals Inc – Key Information
Xenon Pharmaceuticals Inc – Overview
Xenon Pharmaceuticals Inc – Key Employees
Xenon Pharmaceuticals Inc – Key Employee Biographies
Xenon Pharmaceuticals Inc – Key Operational Heads
Xenon Pharmaceuticals Inc – Major Products and Services
Xenon Pharmaceuticals Inc – History
Xenon Pharmaceuticals Inc – Company Statement
Xenon Pharmaceuticals Inc – Locations And Subsidiaries
Xenon Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Xenon Pharmaceuticals Inc – Business Description
Xenon Pharmaceuticals Inc – Corporate Strategy
Xenon Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Xenon Pharmaceuticals Inc – Strengths
Xenon Pharmaceuticals Inc – Weaknesses
Xenon Pharmaceuticals Inc – Opportunities
Xenon Pharmaceuticals Inc – Threats
Xenon Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Xenon Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Xenon Pharmaceuticals Inc, Key Information
Xenon Pharmaceuticals Inc, Key Ratios
Xenon Pharmaceuticals Inc, Share Data
Xenon Pharmaceuticals Inc, Major Products and Services
Xenon Pharmaceuticals Inc, History
Xenon Pharmaceuticals Inc, Key Employees
Xenon Pharmaceuticals Inc, Key Employee Biographies
Xenon Pharmaceuticals Inc, Key Operational Heads
Xenon Pharmaceuticals Inc, Other Locations
Xenon Pharmaceuticals Inc, Subsidiaries
Xenon Pharmaceuticals Inc, Key Competitors
Xenon Pharmaceuticals Inc, SWOT Analysis
Xenon Pharmaceuticals Inc, Ratios based on current share price
Xenon Pharmaceuticals Inc, Annual Ratios
Xenon Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Xenon Pharmaceuticals Inc (XENE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lear Corporation (LEA):企業の財務・戦略的SWOT分析
    Lear Corporation (LEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Array BioPharma Inc (ARRY):製薬・医療:M&Aディール及び事業提携情報
    Summary Array BioPharma Inc (Array) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of targeted small-molecule drugs indicated for the treatment of cancer and inflammatory diseases. The company’s most advanced wholly-owned clinical stage drugs includ …
  • Unitil Corp (UTL):企業の財務・戦略的SWOT分析
    Summary Unitil Corp (Unitil) is an interstate electricity and natural gas utility company. The company offers construction, operation and maintenance of gas and electric distribution systems. Unitil offers business operations such as electricity distribution, gas distribution utility operations and …
  • NextEra Energy Inc (NEE):石油・ガス:M&Aディール及び事業提携情報
    Summary NextEra Energy, Inc. (NEE), formerly FPL Group, Inc., is an electric power and energy infrastructure company that generates, transmits and distributes electricity together with its subsidiaries. The company generates power through various sources such as nuclear, coal, oil and natural gas-fi …
  • Ariste Medical LLC:医療機器:M&Aディール及び事業提携情報
    Summary Ariste Medical LLC (Ariste) is a medical device company that develops drug eluting surgical implants. The company develops drug eluting tunneled dialysis catheter for hemodialysis, drug eluting mesh for hernia repair, and drug eluting vascular graft for peripheral bypass. It also develops dr …
  • MSL Solutions Limited (MPW):企業の財務・戦略的SWOT分析
    MSL Solutions Limited (MPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Per Aarsleff Holding AS (PAAL B):企業の財務・戦略的SWOT分析
    Per Aarsleff Holding AS (PAAL B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Advanced Info Service PLC (ADVANC):企業の財務・戦略的SWOT分析
    Advanced Info Service PLC (ADVANC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • The Jim Pattison Group:企業の戦略・SWOT・財務情報
    The Jim Pattison Group - Strategy, SWOT and Corporate Finance Report Summary The Jim Pattison Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • StealthGas Inc (GASS):石油・ガス:M&Aディール及び事業提携情報
    Summary StealthGas Inc (StealthGas) is an oil and gas shipping company that offers seaborne and oil and gas transportation services. The company provides transportation of petroleum and petrochemical gas products in liquefied forms. It transports byproducts of crude oil and natural gas including but …
  • MITIE Group plc (MTO):企業の財務・戦略的SWOT分析
    MITIE Group plc (MTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Allena Pharmaceuticals Inc (ALNA):製薬・医療:M&Aディール及び事業提携情報
    Summary Allena Pharmaceuticals Inc (Allena) is a developer of oral enzyme therapeutics to treat patients with rare and severe metabolic disorders. The company develops ALLN-177, an oral recombinant oxalate degrading enzyme. It provides ALLN-177 which is developed for the chronic management of hypero …
  • Sally Beauty Holdings, Inc.:企業の戦略・SWOT・財務情報
    Sally Beauty Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sally Beauty Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Topy Industries Ltd:企業の戦略・SWOT・財務情報
    Topy Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Topy Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • PTC, Inc. (PTC):企業の財務・戦略的SWOT分析
    PTC, Inc. (PTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Advanced Proteome Therapeutics Corp (APC):企業の財務・戦略的SWOT分析
    Advanced Proteome Therapeutics Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Emmi AG:企業のM&A・事業提携・投資動向
    Emmi AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Emmi AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Biomay AG-製薬・医療分野:企業M&A・提携分析
    Summary Biomay AG (Biomay) discovers and develops disease modifying allergy therapeutics. The company develops peptide carrier fusion vaccines for allergy immunotherapy. Its pipeline product portfolio comprises investigation candidates targeted against IgE mediated diseases, grass pollen allergy, ho …
  • ImmunoCellular Therapeutics Ltd (IMUC):製薬・医療:M&Aディール及び事業提携情報
    Summary ImmunoCellular Therapeutics Ltd (IMCU) is a clinical-stage biotechnology company which develops immune-based therapies for the treatment of various cancers. The product pipeline of the company includes active immunotherapies and patented monoclonal antibodies. IMCU’s immunotherapies product …
  • Analytik Jena AG:医療機器:M&Aディール及び事業提携情報
    Summary Analytik Jena AG (Analytik Jena), a subsidiary of Endress+Hauser AG is a provider of instruments and products for analytical measuring technology and life science. The company’s major products include atomic spectrometers, optical emission spectroscopy devices, mass spectrometers, mercury an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆